A phase 3 trial of the Scorpion-originated tersolisib will be in first-line breast cancer.
ApexOnco Front Page
Recent articles
So who else could be interested in the oestrogen degrader?
NVL-330 features among the latest crop of industry projects newly into human trials.
BioNTech and Genmab's acasunlimab is the latest 4-1BB project to stumble.
Darzalex added another string to its bow, while Kisqali’s early use has been delayed.
More bad news for CD47 as response rates in Aspen-06 wane, and the company turns to a subgroup.
The company stops dosing in the troubled Tamarack trial, and is going quiet until ESMO.
The companies hope to be as efficacious as ex vivo therapy, with convenience and safety advantages.